spacer
home > ebr > summer 2003 > the cognitive assessment of herbal products - are the effects imagined or real?
PUBLICATIONS
European Biopharmaceutical Review

The Cognitive Assessment of Herbal Products - Are the Effects Imagined or Real?

With the recent proposal by the EU Commission for a Directive on so-called 'traditional herbal products', it would seem that it is no longer possible for companies producing herbal products to simply put them in the marketplace. For years now, many herbal products have been marketed as cognitive enhancers or herbal antidepressants with little or no evidence to substantiate the claims except that they 'have been used traditionally for centuries'. The new EU Directive insists that any herbal products be treated as the medicines they claim to be, rather than seeking the protection of national food laws. Therefore, new and existing herbal compounds will be required to prove 'qualitative, efficacious and safe' results in structured clinical trials. The main disadvantage of the new law, which will have a major adverse impact on the trade of herbal remedies, is that products which cannot claim 30 years of established use will have to seek market authorisation as medicinal products. In this sense, the new Directive's ostensible intention to minimise cost burdens on small and medium-sized producers will also have the unpleasant effect of deleting several little-known herbal products from the EU market altogether.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Tamsin Manktelow, Scientific Development Manager, and Andrea Zangara, Research Associate, at Cognitive Drug Research Ltd

Having graduated from the University of Reading with a BA Hons in Psychology, Tamsin Manktelow has worked as a Clinical Assistant with adolescents suffering from eating disorders, and as a Clinical Audit and Research Assistant.

She joined CDR in June 2000 as a Research Assistant and now oversees the academic arm as Scientific Development Manager. Tamsin is registered at the University of Northumbria for a part-time PhD studying the cognitive effects of eating disorders.

Andrea Zangara joined Cognitive Drug Research Ltd (CDR) in September 2000 having been a Research Assistant at University College London for a year. During this time Andrea researched the effects of a beta-adrenergic blocker and a benzodiazepine upon the recognition of human facial expressions and has since published his work.

Currently, Andrea is a Research Associate at CDR and oversees a number of single and multi-centre projects. He is registered at the University of Northumbria for a part-time PhD examining the cognitive effects of Huperzine.

spacer
Tamsin Manktelow
spacer
spacer
spacer
Andrea Zangara
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Smart Bioprocessing with the new Eppendorf Control System

Hamburg, February 12, 2020 Working with flexible systems that evolve with the changing needs in a lab is indispensable. With the SciVario twin, Eppendorf, a key life science company, introduces its latest bioreactor control system for small- and bench-scale applications. The intelligent controller and new, innovative bay-drawer system enables the exchange of standardized modules to flexibly adapt the controller to the changing requirements in a laboratory.
More info >>

White Papers

Customising the Cold Chain

World Courier

Of all the statistics emerging around the global pharmaceutical industry this year, two big numbers capture the attention of both manufacturers and their logistics partners: $248 billion, the amount the “BRIC” nations (Brazil, Russia, India and China) are poised to account for in pharmaceutical sales for by 2016; and $8 billion, the amount global pharma will spend on cold chain logistics in 2014. Why are these two numbers so noteworthy? They demonstrate that as R&D goes, so goes logistics. As products evolve to meet demands for more targeted therapies, demand for more targeted logistics solutions grows as well. And that means a need for customization for everything from clinical trial samples to finished product.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement